Incyte: Buy For The Turnaround, Stay For The Pipeline (NASDAQ:INCY)

Core Insights - The article highlights the professional background of Brendan, who has extensive experience in the pharmaceutical and biotechnology sectors, including a Ph.D. in organic synthesis from Stanford University and significant roles at major companies like Merck and 1200 Pharma [1] Group 1: Professional Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013, gaining experience in a major pharmaceutical company [1] - Brendan has been involved in biotech startups, including Theravance and Aspira, before joining Caltech [1] Group 2: Entrepreneurial Ventures - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured major investments in the eight-figure range [1] - Brendan remains an avid investor, focusing on market trends, particularly in biotechnology stocks [1]